Terms: = Ovarian cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Prognosis
43 results:
1. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract] [Full Text] [Related]
4. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract] [Full Text] [Related]
5. Association of immunohistochemical profiles with histotypes in endometrial carcinomas.
Lin CM; Lin SF; Lee YC; Lai HC; Liew PL
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):823-829. PubMed ID: 36088051
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathologic association and prognostic impact of microcystic, elongated and fragmented pattern invasion, combined with tumor budding in endometrioid endometrial cancer.
Qi X; Zhu L; Zhang B
J Obstet Gynaecol Res; 2022 Sep; 48(9):2431-2441. PubMed ID: 35769021
[TBL] [Abstract] [Full Text] [Related]
7. The clinical features and management of Lynch syndrome-associated ovarian cancer.
Ran X; Jing H; Li Z
J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
[TBL] [Abstract] [Full Text] [Related]
8. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.
Ye S; Zhou S; Zhong S; Shan B; Jiang W; Yang W; Cai X; Yang H
BMC Cancer; 2022 Apr; 22(1):449. PubMed ID: 35461222
[TBL] [Abstract] [Full Text] [Related]
9. The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma.
Liu X; Ma H; Ma L; Li K; Kang Y
Bioengineered; 2022 Mar; 13(3):5525-5536. PubMed ID: 35166644
[TBL] [Abstract] [Full Text] [Related]
10. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
Sahin I; Saat H
Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
[No Abstract] [Full Text] [Related]
11. RNA-binding protein with serine-rich domain 1 regulates microsatellite instability of uterine corpus endometrial adenocarcinoma.
Liu X; Ma H; Ma L; Li K; Kang Y
Clinics (Sao Paulo); 2021; 76():e3318. PubMed ID: 34817046
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of Diagnosed Lynch Syndrome in a Patient with Ureteral cancer].
Kobayashi G; Takayanagi A; Shindo T; Hashimoto K; Kobayashi K; Fukuta F; Tanaka T; Masumori N
Hinyokika Kiyo; 2021 Jun; 67(6):229-232. PubMed ID: 34265897
[TBL] [Abstract] [Full Text] [Related]
14. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract] [Full Text] [Related]
16. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes.
Bogani G; Tibiletti MG; Ricci MT; Carnevali I; Liberale V; Paolini B; Milione M; Vitellaro M; Murgia F; Chiappa V; Ditto A; Ghezzi F; Raspagliesi F
Int J Gynecol Cancer; 2020 Jan; 30(1):56-61. PubMed ID: 31780564
[TBL] [Abstract] [Full Text] [Related]
17. cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.
Dominguez-Valentin M; Sampson JR; Seppälä TT; Ten Broeke SW; Plazzer JP; Nakken S; Engel C; Aretz S; Jenkins MA; Sunde L; Bernstein I; Capella G; Balaguer F; Thomas H; Evans DG; Burn J; Greenblatt M; Hovig E; de Vos Tot Nederveen Cappel WH; Sijmons RH; Bertario L; Tibiletti MG; Cavestro GM; Lindblom A; Della Valle A; Lopez-Köstner F; Gluck N; Katz LH; Heinimann K; Vaccaro CA; Büttner R; Görgens H; Holinski-Feder E; Morak M; Holzapfel S; Hüneburg R; Knebel Doeberitz MV; Loeffler M; Rahner N; Schackert HK; Steinke-Lange V; Schmiegel W; Vangala D; Pylvänäinen K; Renkonen-Sinisalo L; Hopper JL; Win AK; Haile RW; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Wadt K; Therkildsen C; Okkels H; Ketabi Z; Moreira L; Sánchez A; Serra-Burriel M; Pineda M; Navarro M; Blanco I; Green K; Lalloo F; Crosbie EJ; Hill J; Denton OG; Frayling IM; Rødland EA; Vasen H; Mints M; Neffa F; Esperon P; Alvarez K; Kariv R; Rosner G; Pinero TA; Gonzalez ML; Kalfayan P; Tjandra D; Winship IM; Macrae F; Möslein G; Mecklin JP; Nielsen M; Møller P
Genet Med; 2020 Jan; 22(1):15-25. PubMed ID: 31337882
[TBL] [Abstract] [Full Text] [Related]
18. The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor prognosis and Tumor Lymphocyte Infiltration.
Miyamoto M; Takano M; Tsuda H; Matsuura H; Sakamoto T; Takasaki K; Kato K; Soyama H; Aoyama T; Ishibashi H; Iwahashi H; Furuya K
Pathol Oncol Res; 2020 Apr; 26(2):783-790. PubMed ID: 30810895
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract] [Full Text] [Related]
20. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
[Next]
